RU2017105476A - Соединения - Google Patents

Соединения Download PDF

Info

Publication number
RU2017105476A
RU2017105476A RU2017105476A RU2017105476A RU2017105476A RU 2017105476 A RU2017105476 A RU 2017105476A RU 2017105476 A RU2017105476 A RU 2017105476A RU 2017105476 A RU2017105476 A RU 2017105476A RU 2017105476 A RU2017105476 A RU 2017105476A
Authority
RU
Russia
Prior art keywords
group
alkyl
compound
ring
optionally substituted
Prior art date
Application number
RU2017105476A
Other languages
English (en)
Russian (ru)
Other versions
RU2017105476A3 (enExample
Inventor
Цзехун Вань
Сяомин Чжан
Цзянь ВАН
Мэттью Роберт СЕНДЕР
Эрик Стивен Манас
Рафаэль Энтони РИВЕРО
Джозеф Е. ПЕРО
Кристофер Эрнст НЕИПП
Випулкумар Кантибхай Пател
Original Assignee
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед filed Critical Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед
Publication of RU2017105476A publication Critical patent/RU2017105476A/ru
Publication of RU2017105476A3 publication Critical patent/RU2017105476A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2017105476A 2014-07-22 2015-07-21 Соединения RU2017105476A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2014000695 2014-07-22
CNPCT/CN2014/000695 2014-07-22
PCT/CN2015/084606 WO2016011930A1 (en) 2014-07-22 2015-07-21 Compounds

Publications (2)

Publication Number Publication Date
RU2017105476A true RU2017105476A (ru) 2018-08-28
RU2017105476A3 RU2017105476A3 (enExample) 2019-02-28

Family

ID=55162512

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2017105476A RU2017105476A (ru) 2014-07-22 2015-07-21 Соединения
RU2017105353A RU2690190C2 (ru) 2014-07-22 2015-07-21 Соединения

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2017105353A RU2690190C2 (ru) 2014-07-22 2015-07-21 Соединения

Country Status (14)

Country Link
US (5) US9783546B2 (enExample)
EP (2) EP3172211B1 (enExample)
JP (2) JP6625603B2 (enExample)
KR (2) KR20170029516A (enExample)
CN (2) CN106536521B (enExample)
AR (1) AR101261A1 (enExample)
AU (2) AU2015292049B2 (enExample)
BR (1) BR112016030939B1 (enExample)
CA (2) CA2970537C (enExample)
ES (2) ES2744339T3 (enExample)
RU (2) RU2017105476A (enExample)
TW (1) TW201617348A (enExample)
UY (1) UY36224A (enExample)
WO (2) WO2016011931A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2690190C2 (ru) * 2014-07-22 2019-05-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Соединения

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11273176B2 (en) 2016-03-02 2022-03-15 The Brigham And Women's Hospital, Inc. Use of PLA2G5-deficient suppressive macrophages in suppression of inflammation
ES2907130T3 (es) * 2017-09-26 2022-04-22 Inst Nat Sante Rech Med Darapladib radiomarcado, análogos del mismo y su uso como compuestos para la obtención de imágenes
CN109988126B (zh) * 2017-12-29 2023-05-16 南京富润凯德生物医药有限公司 一种3-氨基-氧杂环丁烷衍生物及其制备方法和应用
CN109134523A (zh) * 2018-09-30 2019-01-04 中昊(大连)化工研究设计院有限公司 一种3，6-二氢-2h-吡喃-4-硼酸频哪醇酯的合成新工艺
JP2022116370A (ja) * 2019-06-13 2022-08-10 アグロカネショウ株式会社 新規な１－ベンジルアミン誘導体及びこれを有効成分とする農園芸用薬剤
CN112574221B (zh) * 2019-09-30 2022-03-04 上海纽思克生物科技有限公司 四环嘧啶酮类化合物、其制备方法、其组合物和用途
CN114805389B (zh) * 2019-11-09 2023-08-29 上海赛默罗生物科技有限公司 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途
CN113666930B (zh) * 2020-05-13 2022-10-25 上海纽思克生物科技有限公司 桥环嘧啶酮类化合物、其制备方法、其组合物和用途
JP7595964B2 (ja) * 2020-05-13 2024-12-09 上海紐思克生物科技有限公司 架橋環状ピリミジノン類化合物、その製造方法、その組成物及び使用
CN113861220B (zh) * 2020-06-30 2023-06-16 上海纽思克生物科技有限公司 三环嘧啶酮类化合物、其制备方法、其组合物和用途
CN113912622B (zh) * 2020-07-10 2023-12-01 上海纽思克生物科技有限公司 三环嘧啶酮类化合物、其制备方法、其组合物和用途
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途
CN114057740B (zh) * 2021-12-15 2024-04-02 上海赛默罗生物科技有限公司 螺环嘧啶酮衍生物、其制备方法、药物组合物和用途
JP2025527291A (ja) * 2022-08-04 2025-08-20 ４ビー テクノロジーズ （ベイジン） カンパニー リミテッド Ｌｐ－ＰＬＡ２阻害剤としてのジヒドロイミダゾピリミジノン化合物およびその使用
JP2026516205A (ja) * 2023-04-18 2026-05-20 サイニューロ セラピューティクス インコーポレイテッド Ｌｐ－ｐｌａ２阻害剤と第２の薬剤の併用治療
CN118221687B (zh) * 2023-07-17 2024-12-31 上海枢境生物科技有限公司 双环[5,6]咪唑嘧啶酮类衍生物、其制备方法和应用
WO2025217646A1 (en) * 2024-04-12 2025-10-16 Scineuro Therapeutics Inc. Method of treating neurodegenerative and ocular neovascular diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0127143D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
AU2003250470A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
GB0320522D0 (en) 2003-09-02 2003-10-01 Glaxo Group Ltd Formulation
WO2009147476A1 (en) 2008-06-02 2009-12-10 Matrix Laboratories Ltd. Novel pde inhibitors, pharmaceutical compositions containing them and processes for their preparation
EP2619203A4 (en) * 2010-09-20 2014-04-16 Glaxo Group Ltd TRICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND APPLICATIONS THEREOF
EP2651403B1 (en) * 2010-12-17 2020-12-02 Glaxo Group Limited Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
CA2835707C (en) * 2011-05-09 2019-02-26 Eip Pharma, Llc Compositions and methods for treating alzheimer's disease
US9273054B2 (en) * 2011-07-27 2016-03-01 Glaxo Group Limited Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors
EP2739627A4 (en) * 2011-07-27 2015-01-21 Glaxo Group Ltd 2,3-DIHYDROIMIDAZO- [1,2-C-] PYRIMIDIN-5 (1H) -ONE COMPOUNDS AS LP-PLA² INHIBITORS
EP2768517A4 (en) 2011-10-17 2015-03-11 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
JP6065786B2 (ja) 2012-09-14 2017-01-25 信越化学工業株式会社 化学増幅レジスト材料及びパターン形成方法
JP2016505053A (ja) 2013-01-25 2016-02-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｌｐ‐ＰＬＡ２の阻害剤としての二環式ピリミドン化合物
WO2014114694A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors
CN103927116A (zh) * 2014-03-18 2014-07-16 兴唐通信科技有限公司 基于触屏设备的手势输入汉字的键盘和方法
EP3172211B1 (en) * 2014-07-22 2019-07-03 GlaxoSmithKline Intellectual Property Development Limited Tricyclic imidazo-pyrimidinone derivatives for the treatment of diseases mediated by lp-pla2

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2690190C2 (ru) * 2014-07-22 2019-05-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Соединения

Also Published As

Publication number Publication date
CA2970537A1 (en) 2016-01-28
US10428078B2 (en) 2019-10-01
RU2017105353A (ru) 2018-08-22
CA2955910A1 (en) 2016-01-28
CN106536521A (zh) 2017-03-22
EP3172211B1 (en) 2019-07-03
JP2017520613A (ja) 2017-07-27
CA2955910C (en) 2022-07-12
ES2744339T3 (es) 2020-02-24
AU2015292049B2 (en) 2017-06-15
CN106536525A (zh) 2017-03-22
AR101261A1 (es) 2016-12-07
UY36224A (es) 2016-01-29
BR112016030939B1 (pt) 2023-10-24
US11999746B2 (en) 2024-06-04
ES2747636T3 (es) 2020-03-11
RU2017105476A3 (enExample) 2019-02-28
JP2017521456A (ja) 2017-08-03
JP6625603B2 (ja) 2019-12-25
CN106536521B (zh) 2018-08-03
AU2015292048A1 (en) 2016-12-15
AU2015292048B2 (en) 2017-06-29
US20200055863A1 (en) 2020-02-20
EP3172211A1 (en) 2017-05-31
EP3172208B1 (en) 2019-06-12
BR112016030939A2 (enExample) 2017-08-22
EP3172208A4 (en) 2017-12-06
US20170204109A1 (en) 2017-07-20
KR20170034889A (ko) 2017-03-29
WO2016011931A1 (en) 2016-01-28
US20240300965A1 (en) 2024-09-12
CN106536525B (zh) 2019-05-03
AU2015292049A1 (en) 2016-12-15
WO2016011930A1 (en) 2016-01-28
EP3172208A1 (en) 2017-05-31
US9783546B2 (en) 2017-10-10
US10125141B2 (en) 2018-11-13
BR112016028591A2 (pt) 2017-08-22
EP3172211A4 (en) 2018-02-14
RU2690190C2 (ru) 2019-05-31
US20170204108A1 (en) 2017-07-20
JP6625604B2 (ja) 2019-12-25
US20190023715A1 (en) 2019-01-24
RU2017105353A3 (enExample) 2018-11-26
TW201617348A (zh) 2016-05-16
CA2970537C (en) 2023-02-21
KR20170029516A (ko) 2017-03-15

Similar Documents

Publication Publication Date Title
JP2016503785A5 (enExample)
RU2348617C2 (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
RU2012119488A (ru) Конденсированные азиновые производные для лечения заболеваний, связанных с ацетилхолиновым рецептором
JP2016506960A5 (enExample)
RU2018125277A (ru) Кристаллическая форма ингибитора тирозинкиназы брутона и способ её получения
PE20181144A1 (es) Derivados de heteroarilo como inhibidores de parp
JP2018502877A5 (enExample)
RU2012148246A (ru) 5, 7- замещенные-имидазо[1, 2-с]пиримидины как ингибиторы jak-киназ
RU2018114289A (ru) Бициклические соединения в качестве ингибиторов аутотаксина (atx)
JP2015504091A5 (enExample)
JP2018524390A5 (enExample)
MA38323A1 (fr) Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale
WO2015083130A1 (en) Fused pyridine and pyrimidine derivatives as ror gamma modulators
RU2018106453A (ru) Соединения
NZ622072A (en) Synthetic methods for spiro-oxindole compounds
MX2010001677A (es) Derivados de 4-(9-(3,3-difluorociclopentil)-5,7,7-trimetil-6-oxo-6 ,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-2-ilamino)-3-me toxibenzamida como inhibidores de las proteinas cinasas humanas plk1 a plk4 para el tratamiento de enfermedades proli
JP2020502092A5 (enExample)
CA2647036A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
ME02838B (me) 3,4-dihidroizokinolin-2(1h)-ilni spojevi
JP2016501185A5 (enExample)
JP2009534358A5 (enExample)
JP2012522766A5 (enExample)
IL257392A (en) The troarils are converted to pyrazolil and their use as drugs
RU2018133391A (ru) 1,5-дигидро-4н-пиразоло[3,4-d]пиримидин-4-оны и 1,5-дигидро-4н-пиразоло[4,3-c]пиридин-4-оны в качестве ингибиторов pde1
RU2435760C2 (ru) 1н-хиназолин-2,4-дионы

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20190716